Clinical Research Directory

Inclusion Criteria: * Age 18 years or older. * Patient for whom at least one mutation deemed of interest by the investigator has been identified. * Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care. * Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study. * INR \< 1.5; Platelets \> 50,000/μL. * Patient who has been informed of the study and has signed the informed consent form. * Patient affiliated with a social security insurance. Exclusion Criteria: * Patient with multiple primary malignant tumors. * Patient with a known HIV, Hepatitis C, or Hepatitis B infection. * Patient on: * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days, * Low molecular weight heparin with no possibility of dose suspension before the procedure, * Fondaparinux with no possibility of suspension, * Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s, * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure, * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure, * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure. * Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8: * Pregnant women, parturients, and breastfeeding mothers, * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research, * Adults under legal protection or unable to express their consent.